A new procoagulant in acute leukemia

Blood. 1988 Apr;71(4):870-5.

Abstract

To verify whether cancer procoagulant (CP), a cysteine proteinase procoagulant distinct from tissue factor (TF), is associated with leukemic cells, we assayed the procoagulant activity of blast cell extracts from 26 patients with different cytological subtypes of acute nonlymphoid leukemia (ANLL) according to the French-American-British classification. All the samples except two shortened the recalcification time of normal human plasma, the effect being significantly greater in the M3 subgroup. The two criteria used to distinguish between CP and TF, independence from factor VII in initiating blood coagulation and sensitivity to cysteine-proteinase inhibitors, were positive in 19 samples from M1, M2, M3, and M4 cytological subtypes. None of the M5 samples fulfilled these criteria. In addition, M1, M2, M3, and M4 samples immunoreacted with an anti-CP goat polyclonal antibody on an Ouchterlony immunodiffusion plate. This study provides the first evidence for a procoagulant other than TF that is associated with leukemic cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Blood Coagulation / drug effects
  • Blood Coagulation Factors / antagonists & inhibitors
  • Blood Coagulation Factors / physiology*
  • Blood Coagulation Tests
  • Cysteine Endopeptidases / blood*
  • Cysteine Endopeptidases / physiology
  • Cysteine Proteinase Inhibitors
  • Female
  • Humans
  • Iodoacetamide / pharmacology
  • Leukemia / blood*
  • Leukemia / enzymology
  • Male
  • Mercuric Chloride / pharmacology
  • Middle Aged
  • Neoplasm Proteins*

Substances

  • Blood Coagulation Factors
  • Cysteine Proteinase Inhibitors
  • Neoplasm Proteins
  • Mercuric Chloride
  • Cysteine Endopeptidases
  • cancer procoagulant
  • Iodoacetamide